Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs IMCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

IMCR Overall Winner 6-Pillar Tally: ZBIO 1 – 5 IMCR Matrix Metrics: ZBIO 4 – 5 IMCR

As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas IMCR carries 46.3/100 (HOLD) at $28.88 (23.8x Forward P/E, -2.2% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs IMCR
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
IMCR NASDAQ Head-to-Head Winner
Immunocore Holdings plc American Depositary Shares
Biological Products, (No Disgnostic Substances)
$28.88
-3.54% 1D
Market Cap $1.6B
TTM Revenue $429M
Forward P/E 23.8x
Beta / 30D Vol 0.63β · 59% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 46.0 Fund 50.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.2%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $30.96 · SMA50: $30.93

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 1 – 5 IMCR)

Columns: Metric · ZBIO · IMCR
1. Valuation Multiples IMCR
Forward P/E N/M 23.8x
Trailing P/E N/M 23.8x
PEG Ratio N/M N/M
EV / Revenue N/M 3.7x
2. Growth & Scale IMCR
Revenue Growth (YoY) -100.0% -1.4%
Earnings Growth (YoY) +0.0% +150.0%
TTM Revenue (USD) $11M $429M
Market Cap $1.9B $1.6B
3. Profitability & Quality IMCR
Gross Margin N/A 34.5%
Operating Margin -2747.5% -2.2%
Net Profit Margin 0.0% -7.5%
Return on Equity (ROE) -265.1% -7.9%
4. Balance Sheet & Cash Flow IMCR
Cash Generation (TTM) -$273M -$5.4M EBITDA
Cash Flow Margin N/A -1.3% EBITDA Mgn
Net Cash / Leverage $177M Net Cash $8.13 Book/Sh · -7.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 95.3% (12th %ile) 56.7% (10th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IMCR
OpEx & R&D Intensity N/A 36.7% of Rev ($158M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (4) vs IMCR (5)
Institutional Metric ZBIO IMCR Criterion Row Edge
Market Capitalization
Scale
$1.9B $1.6B Larger Scale ZBIO
Trailing P/E Ratio
Valuation
N/M 23.8x Lower Multiple IMCR
Forward P/E Ratio
Valuation
N/M 23.8x Lower Multiple IMCR
Revenue Growth (YoY)
Growth
-100.0% -1.4% Higher Growth IMCR
Operating Margin (TTM)
Profitability
-2747.5% -2.2% Higher Margin IMCR
Net Profit Margin
Profitability
0.0% -7.5% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
-265.1% -7.9% Higher ROE IMCR
52-Week Range Position
Momentum
46% ($14–$45) 10% ($28–$41) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 0.63β · 59% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$11M $429M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 34.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) -$5.4M EBITDA ($8.13 Book/Sh · -7.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +14.21 pp
ZBIO: +12.44% · IMCR: -1.77%
3M Horizon ZBIO +7.35 pp
ZBIO: -12.47% · IMCR: -19.82%
6M Horizon ZBIO +63.37 pp
ZBIO: +65.17% · IMCR: +1.8%
1Y Horizon IMCR +3.33 pp
ZBIO: -21.68% · IMCR: -18.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs IMCR. Trailing 12-month operating profitability (ZBIO -2747.5% vs IMCR -2.2%) and valuation multiples (ZBIO N/M vs IMCR 23.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M
IMCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$429M
Gross Margin34.5%
Op. Margin-2.2%
ROE / Fwd P/E-7.9% · 23.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 95.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.7%
IV Percentile 10th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment 36.7% of Rev ($158M)
90D Engineering Disclosures 0 Published

Investor FAQ ZBIO vs IMCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas IMCR carries 46.3/100 (HOLD) at $28.88 (23.8x Forward P/E, -2.2% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMCR leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with IMCR at -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus $429M for IMCR. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus 36.7% of Rev ($158M) (0 disclosures) for IMCR.

IMCR screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMCR trades at 23.8x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-1.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus IMCR (-7.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.